tiprankstipranks
ACADIA Pharmaceuticals (ACAD)
NASDAQ:ACAD
US Market
ACAD
ACADIA Pharmaceuticals
RESEARCH TOOLSreports

ACADIA Pharmaceuticals (ACAD) Stock Forecast & Price Target

2,434 Followers
See the Price Targets and Ratings of:

ACAD Analyst Ratings

Moderate Buy
15Ratings
Moderate Buy
11 Buy
4 Hold
0 Sell
Based on 15 analysts giving stock ratings to
ACADIA
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ACAD Stock 12 Month Forecast

Average Price Target

$32.00
▲(44.14% Upside)
Based on 15 Wall Street analysts offering 12 month price targets for ACADIA Pharmaceuticals in the last 3 months. The average price target is $32.00 with a high forecast of $40.00 and a low forecast of $23.00. The average price target represents a 44.14% change from the last price of $22.20.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"$13","20":"$20","27":"$27","34":"$34","41":"$41"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$40.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$32.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$23.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,20,27,34,41],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.81,24.13230769230769,25.454615384615384,26.776923076923076,28.09923076923077,29.42153846153846,30.743846153846153,32.066153846153846,33.38846153846154,34.71076923076923,36.03307692307692,37.355384615384615,38.67769230769231,{"y":40,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.81,23.516923076923074,24.223846153846154,24.93076923076923,25.637692307692305,26.344615384615384,27.05153846153846,27.75846153846154,28.465384615384615,29.17230769230769,29.87923076923077,30.586153846153845,31.293076923076924,{"y":32,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.81,22.824615384615385,22.839230769230767,22.853846153846153,22.86846153846154,22.88307692307692,22.897692307692306,22.912307692307692,22.926923076923078,22.94153846153846,22.956153846153846,22.970769230769232,22.985384615384614,{"y":23,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":19.6,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.32,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.57,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.465,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.36,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.53,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.69,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.24,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.7,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.85,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.71,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.13,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.81,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$40.00Average Price Target$32.00Lowest Price Target$23.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on ACAD
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$29
Buy
30.63%
Upside
Upgraded
03/25/26
Acadia Pharmaceuticals upgraded to Buy from Neutral at BofAAcadia Pharmaceuticals upgraded to Buy from Neutral at BofA
RBC Capital Analyst forecast on ACAD
Brian Abrahams
RBC Capital
RBC Capital
$30
Buy
35.14%
Upside
Reiterated
03/24/26
RBC Capital Sticks to Their Buy Rating for ACADIA Pharmaceuticals (ACAD)
Mizuho Securities Analyst forecast on ACAD
Uy Ear
Mizuho Securities
Mizuho Securities
$35
Buy
57.66%
Upside
Reiterated
03/05/26
Analysts Conflicted on These Healthcare Names: Hims & Hers Health (NYSE: HIMS) and ACADIA Pharmaceuticals (NASDAQ: ACAD)
J.P. Morgan Analyst forecast on ACAD
Tessa Romero
J.P. Morgan
J.P. Morgan
$34
Buy
53.15%
Upside
Assigned
03/04/26
Acadia Pharmaceuticals price target raised to $34 from $31 at JPMorganAcadia Pharmaceuticals price target raised to $34 from $31 at JPMorgan
H.C. Wainwright Analyst forecast on ACAD
Ananda Ghosh
H.C. Wainwright
H.C. Wainwright
$32→$37
Buy
66.67%
Upside
Reiterated
02/27/26
Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (NASDAQ: SRPT) and ACADIA Pharmaceuticals (NASDAQ: ACAD)
Citi Analyst forecast on ACAD
Yigal Nochomovitz
Citi
Citi
$36→$33
Buy
48.65%
Upside
Reiterated
02/27/26
Acadia Pharmaceuticals price target lowered to $33 from $36 at CitiAcadia Pharmaceuticals price target lowered to $33 from $36 at Citi
TD Cowen Analyst forecast on ACAD
Ritu Baral
TD Cowen
TD Cowen
$35→$37
Buy
66.67%
Upside
Assigned
02/26/26
ACADIA Pharmaceuticals: Accelerating Commercial Momentum and Expanded Outlook Support Raised Price Target and Buy Rating
Needham Analyst forecast on ACAD
Ami Fadia
Needham
Needham
$34→$40
Buy
80.18%
Upside
Reiterated
02/26/26
ACADIA Pharmaceuticals (ACAD) Receives a Buy from Needham
Citizens JMP Analyst forecast on ACAD
Jason Butler
Citizens JMP
Citizens JMP
$34→$35
Buy
57.66%
Upside
Reiterated
02/26/26
Acadia Pharmaceuticals price target raised to $35 from $34 at CitizensAcadia Pharmaceuticals price target raised to $35 from $34 at Citizens
Stifel Nicolaus Analyst forecast on ACAD
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$25→$24
Hold
8.11%
Upside
Reiterated
02/26/26
Acadia Pharmaceuticals price target lowered to $24 from $25 at StifelAcadia Pharmaceuticals price target lowered to $24 from $25 at Stifel
Morgan Stanley Analyst forecast on ACAD
Sean Laaman
Morgan Stanley
Morgan Stanley
$25→$26
Hold
17.12%
Upside
Reiterated
02/26/26
Balancing Robust Nuplazid Outlook and RADIANT Trial Uncertainty: Rationale for Maintaining a Hold on Acadia
Canaccord Genuity Analyst forecast on ACAD
Sumant Kulkarni
Canaccord Genuity
Canaccord Genuity
$32
Buy
44.14%
Upside
Reiterated
02/26/26
Canaccord Genuity Remains a Buy on ACADIA Pharmaceuticals (ACAD)
Guggenheim Analyst forecast on ACAD
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
―
Hold
―
Reiterated
02/26/26
ACADIA Pharmaceuticals (ACAD) Gets a Hold from Guggenheim
Wolfe Research Analyst forecast on ACAD
Rudy Li
Wolfe Research
Wolfe Research
$33
Buy
48.65%
Upside
Initiated
02/23/26
Acadia Pharmaceuticals initiated with an Outperform at Wolfe ResearchAcadia Pharmaceuticals initiated with an Outperform at Wolfe Research
Oppenheimer Analyst forecast on ACAD
Matthew Hershenhorn
Oppenheimer
Oppenheimer
$21→$23
Hold
3.60%
Upside
Reiterated
02/06/26
Acadia Pharmaceuticals price target raised to $23 from $21 at OppenheimerAcadia Pharmaceuticals price target raised to $23 from $21 at Oppenheimer
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on ACAD
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$29
Buy
30.63%
Upside
Upgraded
03/25/26
Acadia Pharmaceuticals upgraded to Buy from Neutral at BofAAcadia Pharmaceuticals upgraded to Buy from Neutral at BofA
RBC Capital Analyst forecast on ACAD
Brian Abrahams
RBC Capital
RBC Capital
$30
Buy
35.14%
Upside
Reiterated
03/24/26
RBC Capital Sticks to Their Buy Rating for ACADIA Pharmaceuticals (ACAD)
Mizuho Securities Analyst forecast on ACAD
Uy Ear
Mizuho Securities
Mizuho Securities
$35
Buy
57.66%
Upside
Reiterated
03/05/26
Analysts Conflicted on These Healthcare Names: Hims & Hers Health (NYSE: HIMS) and ACADIA Pharmaceuticals (NASDAQ: ACAD)
J.P. Morgan Analyst forecast on ACAD
Tessa Romero
J.P. Morgan
J.P. Morgan
$34
Buy
53.15%
Upside
Assigned
03/04/26
Acadia Pharmaceuticals price target raised to $34 from $31 at JPMorganAcadia Pharmaceuticals price target raised to $34 from $31 at JPMorgan
H.C. Wainwright Analyst forecast on ACAD
Ananda Ghosh
H.C. Wainwright
H.C. Wainwright
$32→$37
Buy
66.67%
Upside
Reiterated
02/27/26
Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (NASDAQ: SRPT) and ACADIA Pharmaceuticals (NASDAQ: ACAD)
Citi Analyst forecast on ACAD
Yigal Nochomovitz
Citi
Citi
$36→$33
Buy
48.65%
Upside
Reiterated
02/27/26
Acadia Pharmaceuticals price target lowered to $33 from $36 at CitiAcadia Pharmaceuticals price target lowered to $33 from $36 at Citi
TD Cowen Analyst forecast on ACAD
Ritu Baral
TD Cowen
TD Cowen
$35→$37
Buy
66.67%
Upside
Assigned
02/26/26
ACADIA Pharmaceuticals: Accelerating Commercial Momentum and Expanded Outlook Support Raised Price Target and Buy Rating
Needham Analyst forecast on ACAD
Ami Fadia
Needham
Needham
$34→$40
Buy
80.18%
Upside
Reiterated
02/26/26
ACADIA Pharmaceuticals (ACAD) Receives a Buy from Needham
Citizens JMP Analyst forecast on ACAD
Jason Butler
Citizens JMP
Citizens JMP
$34→$35
Buy
57.66%
Upside
Reiterated
02/26/26
Acadia Pharmaceuticals price target raised to $35 from $34 at CitizensAcadia Pharmaceuticals price target raised to $35 from $34 at Citizens
Stifel Nicolaus Analyst forecast on ACAD
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$25→$24
Hold
8.11%
Upside
Reiterated
02/26/26
Acadia Pharmaceuticals price target lowered to $24 from $25 at StifelAcadia Pharmaceuticals price target lowered to $24 from $25 at Stifel
Morgan Stanley Analyst forecast on ACAD
Sean Laaman
Morgan Stanley
Morgan Stanley
$25→$26
Hold
17.12%
Upside
Reiterated
02/26/26
Balancing Robust Nuplazid Outlook and RADIANT Trial Uncertainty: Rationale for Maintaining a Hold on Acadia
Canaccord Genuity Analyst forecast on ACAD
Sumant Kulkarni
Canaccord Genuity
Canaccord Genuity
$32
Buy
44.14%
Upside
Reiterated
02/26/26
Canaccord Genuity Remains a Buy on ACADIA Pharmaceuticals (ACAD)
Guggenheim Analyst forecast on ACAD
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
―
Hold
―
Reiterated
02/26/26
ACADIA Pharmaceuticals (ACAD) Gets a Hold from Guggenheim
Wolfe Research Analyst forecast on ACAD
Rudy Li
Wolfe Research
Wolfe Research
$33
Buy
48.65%
Upside
Initiated
02/23/26
Acadia Pharmaceuticals initiated with an Outperform at Wolfe ResearchAcadia Pharmaceuticals initiated with an Outperform at Wolfe Research
Oppenheimer Analyst forecast on ACAD
Matthew Hershenhorn
Oppenheimer
Oppenheimer
$21→$23
Hold
3.60%
Upside
Reiterated
02/06/26
Acadia Pharmaceuticals price target raised to $23 from $21 at OppenheimerAcadia Pharmaceuticals price target raised to $23 from $21 at Oppenheimer
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering ACADIA Pharmaceuticals

3 Months
xxx
Success Rate
9/13 ratings generated profit
69%
Average Return
+8.40%
assigned a xxx
 rating last month
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 69.23% of your transactions generating a profit, with an average return of +8.40% per trade.
1 Year
Gregory RenzaTruist Financial
Success Rate
16/30 ratings generated profit
53%
Average Return
+9.95%
reiterated a buy rating 11 months ago
Copying Gregory Renza's trades and holding each position for 1 Year would result in 53.33% of your transactions generating a profit, with an average return of +9.95% per trade.
2 Years
xxx
Success Rate
9/16 ratings generated profit
56%
Average Return
+7.47%
reiterated a xxx
 rating last month
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 56.25% of your transactions generating a profit, with an average return of +7.47% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ACAD Analyst Recommendation Trends

Rating
Nov 25
Dec 25
Jan 26
Feb 26
Mar 26
Strong Buy
12
4
3
4
5
Buy
34
27
26
18
25
Hold
11
7
6
10
14
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
57
38
35
32
44
In the current month, ACAD has received 30 Buy Ratings, 14 Hold Ratings, and 0 Sell Ratings. ACAD average Analyst price target in the past 3 months is 32.00.
Each month's total comprises the sum of three months' worth of ratings.

ACAD Financial Forecast

ACAD Earnings Forecast

Next quarter’s earnings estimate for ACAD is $0.06 with a range of -$0.04 to $0.14. The previous quarter’s EPS was $1.60. ACAD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ACAD has Performed in-line its overall industry.
Next quarter’s earnings estimate for ACAD is $0.06 with a range of -$0.04 to $0.14. The previous quarter’s EPS was $1.60. ACAD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ACAD has Performed in-line its overall industry.

ACAD Sales Forecast

Next quarter’s sales forecast for ACAD is $282.69M with a range of $271.00M to $300.90M. The previous quarter’s sales results were $283.99M. ACAD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ACAD has Performed in-line its overall industry.
Next quarter’s sales forecast for ACAD is $282.69M with a range of $271.00M to $300.90M. The previous quarter’s sales results were $283.99M. ACAD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ACAD has Performed in-line its overall industry.

ACAD Stock Forecast FAQ

What is ACAD’s average 12-month price target, according to analysts?
Based on analyst ratings, ACADIA Pharmaceuticals’s 12-month average price target is 32.00.
    What is ACAD’s upside potential, based on the analysts’ average price target?
    ACADIA Pharmaceuticals has 44.14% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ACAD a Buy, Sell or Hold?
          ACADIA Pharmaceuticals has a consensus rating of Moderate Buy which is based on 11 buy ratings, 4 hold ratings and 0 sell ratings.
            What is ACADIA Pharmaceuticals’s price target?
            The average price target for ACADIA Pharmaceuticals is 32.00. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $40.00 ,the lowest forecast is $23.00. The average price target represents 44.14% Increase from the current price of $22.2.
              What do analysts say about ACADIA Pharmaceuticals?
              ACADIA Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 15 Wall Streets Analysts.
                How can I buy shares of ACAD?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.